Lianyungang Runzhong Pharmaceutical Co., Ltd.
USPTO PatentsView assignee record - 26 granted patents across 8 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Lianyungang ranks #11,715 of 49,997 tracked US assignees by granted-patent volume, with 26 patents across 8 technology areas.
- #11,715
- of 49,997 US assignees by volume
- 43rd percentile
- by Innovation Score (33.1/100)
- 17.1
- avg claims per patent
- +125%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R11715 · Foreign Corporation #11,715 · 26 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
- GRANTS-SMALL 26 grants
- UPPER-Q #11,715/49,997
- PHOTO-FINISH L3vel
- CPC-NARROW A61P · 8 areas
- INNOV-THIN 33.1/100
- CLAIMS-RICH 17.1 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-SURGE +125% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: L3vel, LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Lianyungang’s 33.1 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Lianyungang
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Belden Canada · near 33
Belden Canada · near
33 score
- Canada Goose · near 33
Canada Goose · near
33 score
- Lianyungang… · this assignee 33
Lianyungang… · this assignee
33 score
- Metra · near 33
Metra · near
33 score
- Polymer Ventures · near 33
Polymer Ventures · near
33 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Lianyungang's Innovation Score is 33.1/100 (43rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Lianyungang?
Each dot is one of Lianyungang’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Lianyungang’s own 17.1 claims/patent is ABOVE the 14.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Lianyungang's grants concentrate
Lianyungang Runzhong Pharmaceutical Co., Ltd. is a focused PatentsView assignee: 8 CPC subclasses with 92.3% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (10 grants) versus a trough of 1 in 2022. By volume, Lianyungang sits between L3vel, LLC and Lpkf Laser & Electronics AG.
Lianyungang's three-year grant acceleration
Lianyungang Runzhong Pharmaceutical Co., Ltd. shows 4 grants in 2022–2024 against only 18 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Lianyungang's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- L3vel
L3vel, LLC
26 patents
- Lafarge
Lafarge
26 patents
- Lanxess Solutions…
Lanxess Solutions US Inc.
26 patents
- Lemken & KG
Lemken GmbH & Co. KG
26 patents
- Lilac Solutions
Lilac Solutions, Inc.
26 patents
- Lingsen Precision…
Lingsen Precision Industries, Ltd.
26 patents
- London Health Sci…
London Health Sciences Centre Research Inc.
26 patents
- Lpkf Laser &
Lpkf Laser & Electronics AG
26 patents
- Lianyungang Runzh… ◀
Lianyungang Runzhong Pharmaceutical Co., Ltd.
26 patents
What this shows Lianyungang holds 26 patents at rank #11,711, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Lianyungang
By rank, the assignees closest to #11,711 in granted patent volume.
- L3vel, LLC #11,707 · 26 patents
- Lafarge #11,708 · 26 patents
- Lanxess Solutions US Inc. #11,709 · 26 patents
- Lemken GmbH & Co. KG #11,710 · 26 patents
- Lilac Solutions, Inc. #11,712 · 26 patents
- Lingsen Precision Industries, Ltd. #11,713 · 26 patents
- London Health Sciences Centre Research Inc. #11,714 · 26 patents
- Lpkf Laser & Electronics AG #11,715 · 26 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Lianyungang's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Lianyungang, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Lianyungang ranks #816 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (33 here).
Lianyungang's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
33 43rd percentile higher than 43% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 2 | 7.7% |
| 2018 | 2 | 7.7% |
| 2019 | 4 | 15.4% |
| 2020 | 10 | 38.5% |
| 2021 | 4 | 15.4% |
| 2022 | 1 | 3.8% |
| 2023 | 1 | 3.8% |
| 2024 | 2 | 7.7% |
Which technologies does Lianyungang Runzhong Pharmaceutical Co., Ltd. patent most?
Top 8 of 8 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Lianyungang Runzhong Pharmaceutical Co., Ltd.'s patent record in context - here's where to go next.
- Lianyungang Runzhong Pharmaceutical Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 92.3% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #11,715 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Lianyungang Runzhong Pharmaceutical Co., Ltd. against L3vel, LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 33.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.